OTCPK:CHMMF (Australia)
Â
Ordinary Shares
$
0.10
-0.029 (-96.67%)
10:08 PM EST
Business Description
Chimeric Therapeutics Ltd
ISIN : AU0000121576
Share Class Description:
CHMMF: Ordinary SharesDescription
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.51 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -6.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 41.8 | |||||
3-Year EPS without NRI Growth Rate | 41.6 | |||||
3-Year FCF Growth Rate | 47 | |||||
3-Year Book Growth Rate | -74.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.69 | |||||
Quick Ratio | 0.69 | |||||
Cash Ratio | 0.34 | |||||
Days Sales Outstanding | 8 | |||||
Days Payable | 2104.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.3 | |||||
Shareholder Yield % | -229.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.66 | |||||
Operating Margin % | -380.73 | |||||
Net Margin % | -262.79 | |||||
EBITDA Margin % | -228.7 | |||||
FCF Margin % | -221.56 | |||||
OCF Margin % | -215.33 | |||||
ROE % | -1153.64 | |||||
ROA % | -122.06 | |||||
ROIC % | -98.83 | |||||
3-Year ROIIC % | -132.25 | |||||
ROC (Joel Greenblatt) % | -1846900 | |||||
ROCE % | -397.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.22 | |||||
EV-to-EBIT | -0.22 | |||||
EV-to-Forward-EBIT | -0.86 | |||||
EV-to-EBITDA | -0.22 | |||||
EV-to-Forward-EBITDA | -0.71 | |||||
EV-to-Revenue | 1.03 | |||||
EV-to-FCF | -0.47 | |||||
Earnings Yield (Greenblatt) % | -454.55 | |||||
FCF Yield % | -244.87 |
GF Valueâ„¢
Chimeric Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chimeric Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2026-04-22 | 0.10 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:CHMMF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program | 2026-04-21 |
Articles on Chimeric Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers